Objective:To conduct a meta-analysis assessing the perioperative,functional and oncological outcomes of partial nephrectomy(PN)and radical nephrectomy(RN)for T1b tumours.The primary endpoints were the oncological outc...Objective:To conduct a meta-analysis assessing the perioperative,functional and oncological outcomes of partial nephrectomy(PN)and radical nephrectomy(RN)for T1b tumours.The primary endpoints were the oncological outcomes.The secondary endpoints were the perioperative and functional outcomes.Methods:A systematic literature review was performed by searching multiple databases through February 2019 to identify eligible comparative studies according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement.Identified reports were assessed according to the Newcastle-Ottawa Scale for nonrandomized controlled trials.Results:Overall,13 retrospective cohort studies were included in the analysis.Patients undergoing PN were younger(weighted mean difference[WMD]3.49 years,95%confidence interval[CI]5.16 to1.82;p<0.0001)and had smaller masses(WMD0.45 cm,95%CI0.59 to0.31;p<0.0001).There were no differences in the oncological outcome,which was demonstrated by progression-free survival(hazard ratio[HR]0.70;pZ0.22),cancerspecific mortality(HR 0.91;pZ0.57)and all-cause mortality(HR 1.01;pZ0.96).The two procedures were similar in estimated blood loss(WMD16.47 mL;pZ0.53)and postoperative complications(risk ratio[RR]1.32;pZ0.10),and PN provided better renal function preservation and was related to a lower likelihood of chronic kidney disease onset(RR 0.38;pZ0.006).Conclusion:PN is an effective treatment for T1b tumours because it offers similar surgical morbidity,equivalent cancer control,and better renal preservation compared to RN.展开更多
目的比较单孔腹腔镜根治性肾切除术(LESS-RN)与传统腹腔镜根治性肾切除术(CL-RN)后至少10年的局限性肾癌患者肿瘤疗效和肾功能结局。方法选取2009-2012年在海军军医大学(第二军医大学)第一附属医院接受LESS-RN或CL-RN治疗的T1a~T2a期局...目的比较单孔腹腔镜根治性肾切除术(LESS-RN)与传统腹腔镜根治性肾切除术(CL-RN)后至少10年的局限性肾癌患者肿瘤疗效和肾功能结局。方法选取2009-2012年在海军军医大学(第二军医大学)第一附属医院接受LESS-RN或CL-RN治疗的T1a~T2a期局限性肾癌患者,按患者年龄、BMI、肿瘤大小进行倾向评分匹配,共纳入31对患者,分析患者的基线特征、手术数据、病理结果和随访信息,以评估LESS-RN和CL-RN的长期预后差异。结果LESS-RN组与CL-RN组患者在手术时间[(179.7±43.0)min vs(172.6±50.9)min,P=0.349]、估计失血量[100(50,200)mL vs 100(50,150)mL,P=0.871]、住院时间[6(5,7)d vs 7(6,9)d,P=0.080]方面差异均无统计学意义。LESS-RN组有1例患者发生术中并发症,没有患者发生术后并发症;CL-RN组有1例患者发生术中并发症,3例患者发生术后并发症。LESS-RN组随访时间为(138.0±9.0)个月,CL-RN组为(137.8±9.8)个月(P=0.730)。LESS-RN组与CL-RN组患者总生存率(80.6%vs 74.2%,P=0.181)、肿瘤特异性生存率(93.6%vs 96.8%,P=0.554)、血肌酐变化水平[32(17,45)μmol/L vs 20(5,47)μmol/L,P=0.098]和估算的肾小球滤过率[(60.2±20.9)mL·min^(-1)·(1.73 m^(2))^(-1) vs(66.7±27.8)mL·min^(-1)·(1.73 m^(2))^(-1),P=0.342]差异均无统计学意义。结论LESS-RN是一种安全、可行的治疗局限性肾癌的手术方法,其长期肿瘤疗效和肾功能结局与CL-RN相当。展开更多
文摘Objective:To conduct a meta-analysis assessing the perioperative,functional and oncological outcomes of partial nephrectomy(PN)and radical nephrectomy(RN)for T1b tumours.The primary endpoints were the oncological outcomes.The secondary endpoints were the perioperative and functional outcomes.Methods:A systematic literature review was performed by searching multiple databases through February 2019 to identify eligible comparative studies according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement.Identified reports were assessed according to the Newcastle-Ottawa Scale for nonrandomized controlled trials.Results:Overall,13 retrospective cohort studies were included in the analysis.Patients undergoing PN were younger(weighted mean difference[WMD]3.49 years,95%confidence interval[CI]5.16 to1.82;p<0.0001)and had smaller masses(WMD0.45 cm,95%CI0.59 to0.31;p<0.0001).There were no differences in the oncological outcome,which was demonstrated by progression-free survival(hazard ratio[HR]0.70;pZ0.22),cancerspecific mortality(HR 0.91;pZ0.57)and all-cause mortality(HR 1.01;pZ0.96).The two procedures were similar in estimated blood loss(WMD16.47 mL;pZ0.53)and postoperative complications(risk ratio[RR]1.32;pZ0.10),and PN provided better renal function preservation and was related to a lower likelihood of chronic kidney disease onset(RR 0.38;pZ0.006).Conclusion:PN is an effective treatment for T1b tumours because it offers similar surgical morbidity,equivalent cancer control,and better renal preservation compared to RN.
文摘目的比较单孔腹腔镜根治性肾切除术(LESS-RN)与传统腹腔镜根治性肾切除术(CL-RN)后至少10年的局限性肾癌患者肿瘤疗效和肾功能结局。方法选取2009-2012年在海军军医大学(第二军医大学)第一附属医院接受LESS-RN或CL-RN治疗的T1a~T2a期局限性肾癌患者,按患者年龄、BMI、肿瘤大小进行倾向评分匹配,共纳入31对患者,分析患者的基线特征、手术数据、病理结果和随访信息,以评估LESS-RN和CL-RN的长期预后差异。结果LESS-RN组与CL-RN组患者在手术时间[(179.7±43.0)min vs(172.6±50.9)min,P=0.349]、估计失血量[100(50,200)mL vs 100(50,150)mL,P=0.871]、住院时间[6(5,7)d vs 7(6,9)d,P=0.080]方面差异均无统计学意义。LESS-RN组有1例患者发生术中并发症,没有患者发生术后并发症;CL-RN组有1例患者发生术中并发症,3例患者发生术后并发症。LESS-RN组随访时间为(138.0±9.0)个月,CL-RN组为(137.8±9.8)个月(P=0.730)。LESS-RN组与CL-RN组患者总生存率(80.6%vs 74.2%,P=0.181)、肿瘤特异性生存率(93.6%vs 96.8%,P=0.554)、血肌酐变化水平[32(17,45)μmol/L vs 20(5,47)μmol/L,P=0.098]和估算的肾小球滤过率[(60.2±20.9)mL·min^(-1)·(1.73 m^(2))^(-1) vs(66.7±27.8)mL·min^(-1)·(1.73 m^(2))^(-1),P=0.342]差异均无统计学意义。结论LESS-RN是一种安全、可行的治疗局限性肾癌的手术方法,其长期肿瘤疗效和肾功能结局与CL-RN相当。
